79679-49-5

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Dihydrobenzofuran-5-ethanol Tosylate is used as an intermediate in the synthesis of various pharmaceuticals for its ability to facilitate the production of complex organic molecules.
Used in Agrochemical Industry:
2,3-Dihydrobenzofuran-5-ethanol Tosylate is used as an intermediate in the synthesis of agrochemicals, contributing to the development of effective crop protection agents.
Used in Medicinal Chemistry:
2,3-Dihydrobenzofuran-5-ethanol Tosylate is used as a research compound in medicinal chemistry for its potential role in the discovery and development of new drugs.
Used in Drug Discovery:
2,3-Dihydrobenzofuran-5-ethanol Tosylate is used as a tool in drug discovery processes, aiding in the identification and optimization of lead compounds for therapeutic applications.
Used in Material Science:
2,3-Dihydrobenzofuran-5-ethanol Tosylate is used in the development of new materials and fine chemicals, potentially contributing to advancements in various industries.
It is important to handle and store 2,3-Dihydrobenzofuran-5-ethanol tosylate with care, as it is classified as a hazardous chemical and may pose health and environmental risks if not properly managed.

InChI:InChI=1/C17H18O4S/c1-13-2-5-16(6-3-13)22(18,19)21-11-8-14-4-7-17-15(12-14)9-10-20-17/h2-7,12H,8-11H2,1H3

Upstream product

• 87776-76-9 5-(2-hydroxyethyl)-2,3-dihydrobenzofuran 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 133099-07-7 (S)-darifenacin hydrobromide 

Relevant academic research and scientific papers

AN IMPROVED PROCESS FOR THE PREPARATION OF DARIFENACIN HYDROBROMIDE

The present invention relates to an improved process for the preparation of Darifenacin hydrobromide of Formula (I). (i) condensing 3-(S)-(-)-1l-carbamoyl-1,1-diphenylmethyl)pyrrolidine (III), or its salt, with a compound of Formula XIII in the presence of a. base in a solvent, wherein X represents Cl, Br, C1-3 alkyl sulfonate or C6-10 arγl sulfonate; to produce (S)-2-[1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3- pyrrolidinyl]-2,2-diphenylacetamide (Darifenacin) (Ia), (ix) treating (S)-2-[1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl]- 2,2-diphenylacetamide (Darifenacin) (Ia) with an acid in a solvent and water mixture, (x) isolating pure (S)-2-[1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3- pyrrolidinyl]-2,2-diphenylacetamide (Darifenacin) (Ia), (xi) treating pure Darifenacin (Ia) with HBr to produce Darifenacin hydrobromide (I).

AMINOCYCLOALKANE COMPOUNDS

Aminocycloalkane compounds represented by the following general formula: wherein Ar represents a phenyl group or thienyl group with an optional substituent on the ring, X represents a cyano group or carbamoyl group, R1 and R2 are each independent, R1 representing a hydrogen atom or lower alkyl group and R2 representing a hydrogen atom, lower alkyl group, an -A-B group (where A represents a lower alkylene group that is optionally branched and B represents a phenyl group, pyridyl group, thiazole group, imidazole group, furyl group or pyrrolidinyl group with an optional substituent on the ring) or an alkenyl group, or R1 and R2 together with the nitrogen atom to which they are bonded represent (where R3 represents a hydrogen atom, a lower alkyl group that is optionally substituted with a phenyl group, or an alkenyl group), and m represents 2, 3 or 4, and pharmacologically acceptable salts thereof. The compounds have highly selective antagonistic activity for muscarinic M3 receptor subtypes, and are therefore useful as preventive or therapeutic agents for diseases related to muscarinic M3 receptor subtypes.